SWOG clinical trial number
S9718

A Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Extensive Small Cell Lung Cancer

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Gemcitabine + CDDP in SCLC
Activated
07/01/1998
Closed
06/15/1999

Research committees

Lung Cancer

Publication Information Expand/Collapse

2007

Phase II Study of Gemcitabine and Cisplatin in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group Study 9718 [PMID: 17473660]

PJ Hesketh;K Chansky;V Israel;RT Grapski;TM Mekhail;CH Spiridonidis;GM Mills;K Kelly;JJ Crowley;DR Gandara Journal of Thoracic Oncology 2(5):440-444

2001

Southwest Oncology Group trial (SWOG) S9718: a phase II study of gemcitabine plus cisplatin in patients with extensive small cell lung cancer (E-SCLC)

VP Israel;K Chansky;D Gandara Proc of the American Society of Clinical Oncology 20:316a(#1262)

2000

Gemcitabine and platinum combinations in advanced non-small cell lung cancer: an update

DR Gandara;MJ Edelman;P Lara;D Lau Lung Cancer 29(Suppl.2):7

Other Clinical Trials

SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Management and Survivorship
Activated
03/14/2025
Accrual
2%
Open
Phase